Challenges in COVID-19 Vaccine Rollout: Lessons from the UK
The U.S. can and should cautiously assess the U.K.’s vaccination strategy to avoid challenges that may impede its ability to control the virus.

The U.S. can and should cautiously assess the U.K.’s vaccination strategy to avoid challenges that may impede its ability to control the virus.
We must remain cognizant of the many ways metaphors may distort, divide, or misrepresent important details.
The EUA pathway may impede vital scientific progress needed to establish the long term safety and efficacy of investigational COVID-19 vaccines.
We can simultaneously get COVID vaccines to those most at risk while minimizing harm to our ability to fully evaluate their safety and efficacy.
The rapid deployment of COVID-19 predictive models may have a lasting impact on the oversight of health care AI.
This blog post provides an overview of the FDA’s emergency authorization powers and analyzes the extent of their usage in the COVID-19 pandemic.
Paying for vaccination is dubious public health policy likely to backfire in terms of (re)building public trust in vaccines.
Can private businesses mandate that employees and customers receive COVID-19 vaccines authorized for emergency use?
In the past weeks, three companies in advanced stages of COVID-19 vaccine trials reported good news. What does this mean?
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from October 2020.